PL3522880T3 - Sposoby leczenia ostrego uszkodzenia nerek - Google Patents

Sposoby leczenia ostrego uszkodzenia nerek

Info

Publication number
PL3522880T3
PL3522880T3 PL17787773T PL17787773T PL3522880T3 PL 3522880 T3 PL3522880 T3 PL 3522880T3 PL 17787773 T PL17787773 T PL 17787773T PL 17787773 T PL17787773 T PL 17787773T PL 3522880 T3 PL3522880 T3 PL 3522880T3
Authority
PL
Poland
Prior art keywords
kidneys
treatment
methods
acute damage
acute
Prior art date
Application number
PL17787773T
Other languages
English (en)
Inventor
Bharat Lagu
Michael Patane
Effie Tozzo
Scott Trzaska
Original Assignee
Mitobridge, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge, Inc. filed Critical Mitobridge, Inc.
Publication of PL3522880T3 publication Critical patent/PL3522880T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
PL17787773T 2016-10-05 2017-10-05 Sposoby leczenia ostrego uszkodzenia nerek PL3522880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury
EP17787773.5A EP3522880B1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
PL3522880T3 true PL3522880T3 (pl) 2021-08-23

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17787773T PL3522880T3 (pl) 2016-10-05 2017-10-05 Sposoby leczenia ostrego uszkodzenia nerek

Country Status (33)

Country Link
US (1) US20210283116A1 (pl)
EP (1) EP3522880B1 (pl)
JP (1) JP7065839B2 (pl)
KR (1) KR20190062502A (pl)
CN (1) CN109789117B (pl)
AU (1) AU2017340760B2 (pl)
BR (1) BR112019005539A2 (pl)
CA (1) CA3036723A1 (pl)
CO (1) CO2019004561A2 (pl)
CY (1) CY1124759T1 (pl)
DK (1) DK3522880T3 (pl)
ES (1) ES2859487T3 (pl)
HR (1) HRP20210294T1 (pl)
HU (1) HUE053557T2 (pl)
IL (1) IL265749A (pl)
JO (1) JOP20190056B1 (pl)
LT (1) LT3522880T (pl)
MA (1) MA46459B1 (pl)
MD (1) MD3522880T2 (pl)
MX (1) MX387518B (pl)
MY (1) MY192385A (pl)
PH (1) PH12019500725A1 (pl)
PL (1) PL3522880T3 (pl)
PT (1) PT3522880T (pl)
RS (1) RS61573B1 (pl)
RU (1) RU2753607C2 (pl)
SG (1) SG11201901925RA (pl)
SI (1) SI3522880T1 (pl)
SM (1) SMT202100111T1 (pl)
TW (1) TWI778982B (pl)
UA (1) UA124019C2 (pl)
WO (1) WO2018067857A1 (pl)
ZA (1) ZA201901743B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016333963C1 (en) 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) * 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) * 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
WO2021013772A1 (en) 2019-07-19 2021-01-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3212825A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539403C (en) 2003-09-19 2013-11-19 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
JP2016512201A (ja) 2013-03-08 2016-04-25 アッヴィ・インコーポレイテッド 急性腎障害の治療方法
JP2016520552A (ja) * 2013-04-05 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ Pparアゴニスト
EP2862574A1 (en) 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
CN110007084B (zh) * 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US20170305894A1 (en) * 2014-10-08 2017-10-26 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
AU2016333963C1 (en) * 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof

Also Published As

Publication number Publication date
AU2017340760A1 (en) 2019-03-21
CY1124759T1 (el) 2022-07-22
ES2859487T3 (es) 2021-10-04
RU2019111421A (ru) 2020-11-06
JP2019533660A (ja) 2019-11-21
ZA201901743B (en) 2022-04-28
MA46459B1 (fr) 2021-03-31
MA46459A (fr) 2019-08-14
AU2017340760B2 (en) 2023-07-27
MY192385A (en) 2022-08-18
MX2019003949A (es) 2019-06-10
PT3522880T (pt) 2021-02-22
RS61573B1 (sr) 2021-04-29
SG11201901925RA (en) 2019-04-29
JOP20190056A1 (ar) 2019-03-24
CN109789117A (zh) 2019-05-21
RU2019111421A3 (pl) 2021-02-05
UA124019C2 (uk) 2021-07-07
EP3522880B1 (en) 2020-12-02
WO2018067857A1 (en) 2018-04-12
TWI778982B (zh) 2022-10-01
MD3522880T2 (ro) 2021-03-31
PH12019500725A1 (en) 2019-08-05
SMT202100111T1 (it) 2021-05-07
LT3522880T (lt) 2021-03-25
DK3522880T3 (en) 2021-01-18
TW201815391A (zh) 2018-05-01
MX387518B (es) 2025-03-18
RU2753607C2 (ru) 2021-08-18
CO2019004561A2 (es) 2019-07-31
KR20190062502A (ko) 2019-06-05
CN109789117B (zh) 2022-08-23
JP7065839B2 (ja) 2022-05-12
BR112019005539A2 (pt) 2019-06-18
SI3522880T1 (sl) 2021-07-30
JOP20190056B1 (ar) 2022-03-15
IL265749A (en) 2019-06-30
HRP20210294T1 (hr) 2021-04-16
HUE053557T2 (hu) 2021-07-28
EP3522880A1 (en) 2019-08-14
CA3036723A1 (en) 2018-04-12
US20210283116A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL269371A (en) Treatment methods
PL3507418T3 (pl) Sposoby biopochodnej derywatyzacji powierzchni celulozowych
IL249292A0 (en) Methods and devices for treating pulmonary edema
PL3265053T3 (pl) Sposoby leczenia skóry
IL263680A (en) Combination therapies
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
EP4015648C0 (en) REDUCTION OF INTRON RETENTION
EP3564335A4 (en) SURFACE TREATMENT AGENT
DK3851537T5 (da) Behandling af hyperbilirubinæmi
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
DK3189283T3 (da) Filterhus
DK3231444T3 (da) Ny behandling
LT3007726T (lt) Tautopatijos gydymo būdai
IL242971A0 (en) Ventricular far field reduction
IL256206A (en) Mct4 inhibitors for treating disease
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3223869T3 (da) Gelatineoprensning
EP3375108A4 (en) SELECTIVE WIFI
SI3167011T1 (sl) Postopek sušenja
PL3393468T3 (pl) Metody leczenia niedoboru odporności
EP3551270A4 (en) FILTER ASSEMBLY
IL263440A (en) Methods for treating heterotopic ossification
EP3398042A4 (en) REMOVAL OF BACKGROUND